Protalix (PLX) CEO Bashan Dror Receives 480,000-Unit Award

What Happened

• Bashan Dror, President, CEO and Director of Protalix BioTherapeutics (PLX), was granted two equity awards on 2026-09-03 totaling 480,000 derivative units (320,000 and 160,000). Each grant shows an acquisition price of $0.00 on the Form 4, indicating these are awards/derivative grants (not open-market purchases or sales).

Key Details

• Transaction date: 2026-09-03; filing date: 2026-09-04 (timely).
• Reported price: $0.00 for each award; total reported cash value at grant = $0.
• Vesting: Footnotes indicate the awards are subject to vesting in 12 equal quarterly installments commencing on the grant date (i.e., roughly a 3-year quarterly vesting schedule).
• Award types (per footnotes): filing references both stock-option and restricted stock unit mechanics — options vest quarterly and include accelerated vesting on a corporate transaction/change in control; RSUs each represent the right to receive one share on vesting.
• Other outstanding options: footnotes note additional option grants outstanding (160,000 @ $4.69 exp. 6/30/2029; 750,000 @ $1.03 exp. 9/7/2032; 340,000 @ $1.64 exp. 9/3/2035).
• Shares owned after transaction: not specified in the provided summary of the Form 4.

Context

• These are equity awards (derivative grants), not cash purchases or sales; they generally reflect compensation/retention rather than immediate trading decisions. Vesting and possible accelerated vesting on a change in control are noted in the filing. No sale or exercise occurred in this report.